BETHESDA, Md.--(BUSINESS WIRE)--The Cystic Fibrosis Foundation has agreed to invest up to $15 million in ReCode Therapeutics to support their gene editing collaboration with Intellia Therapeutics. The ...
Artistic rendering of gene editing reagents — mRNA (red) and DNA (green and yellow) constructs — being packaged into a lipid nanoparticle (blue). UCLA researchers have developed a lipid ...
(RTTNews) - Intellia Therapeutics, Inc. (NTLA) Thursday announced a strategic collaboration with ReCode Therapeutics to develop gene editing therapies for Cystic fibrosis. The financial aspect of the ...
Congenital bilateral absence of the vas deferens (CBAVD) is a recognised cause of male infertility most frequently linked to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) ...
Human cells that have been edited with the new retron-based gene editing technology. Orange dots mark successful gene edits. Green dots show a fluorescent protein tag on the surface of mitochondria.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor/tezacaftor/ivacaftor) for the ...
Emily Kramer-Golinkoff can’t get enough oxygen with each breath. Advanced cystic fibrosis makes even simple things like walking or showering arduous and exhausting. She has the most common fatal ...
Individuals with cystic fibrosis show a notably higher rate of attention deficit hyperactivity disorder (ADHD) symptoms than the general population. This association points to a possible role of the ...
The Cystic Fibrosis Foundation is funding the development of a gene editing therapy that is designed to use ReCode’s tissue-specific delivery vehicle to transport gene editing cargo to the lung cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results